#Netherlands #Leiden #Anaheim Bio #ANA-1 #CPPD

Anaheim Bio: Pioneering Treatment for CPPD

Anaheim Bio, a newly launched biotechnology startup, has successfully secured an impressive €40 million in Series A financing aimed at propelling its lead therapeutic candidate, ANA-1, into the clinical trial phase.

Company Overview

Originally spun out from Alesta Therapeutics, Anaheim Bio is committed to developing innovative treatments targeting debilitating conditions. Currently, the company's flagship product, ANA-1, is being designed to address calcium pyrophosphate deposition disease (CPPD), a painful form of inflammatory arthritis that affects millions worldwide.

Ilan Ganot, the CEO of Anaheim Bio, expressed confidence in the impact of ANA-1, stating, "ANA-1 is tailored to directly combat the core pathology of CPPD. It presents a significant opportunity to transform treatment options for those who currently lack effective therapies that directly target the harmful crystal deposits responsible for the disease."

The Challenge of CPPD

Calcium pyrophosphate deposition disease is characterized by the accumulation of calcium pyrophosphate crystals in and around the joints, leading to severe episodes of joint pain and chronic arthritis. This condition primarily affects older adults and is estimated to impact around 4% to 7% of the adult population in Europe and the United States.

While current treatment options primarily focus on managing inflammation and symptom relief, they do not address the underlying issues caused by the crystal deposits. Anaheim Bio aims to fill this critical gap with their new therapeutic solution, predicted to enter clinical testing in 2027.

Financial Backing and Future Plans

Anaheim Bio's recent funding round was described as oversubscribed, thanks to contributions from prominent investors such as Droia Ventures, Frazier Life Sciences, RTW Investments, Novartis Venture Fund, RV Invest, and Thuja Capital. This robust financial backing ensures that the company has sufficient runway to progress through critical IND-enabling studies and onto Phase 1 trials for ANA-1.

Luc Dochez, Chair of Anaheim Bio’s Board of Directors and a Managing Partner at Droia Ventures, emphasized the significance of ANA-1’s development, highlighting it as a potential game changer in the rheumatology field. "With ANA-1, we are targeting one of the largest underserved sectors in rheumatology, which remains a significant unmet medical need, particularly for aging populations."

Anaheim Bio’s Leadership Team

Guided by a dedicated management team, Anaheim Bio is well-prepared for its ambitious journey. Alongside CEO Ilan Ganot, the executive team includes:

• - Matthias Van Woensel, Ph.D., Chief Scientific Officer
• - Rick Dekker, Chief Financial Officer
• - Benit Maru, MBChB, Ph.D., Interim Chief Medical Officer

The Board of Directors features expertise from established professionals in the biotech industry, underscoring the strength of Anaheim Bio’s foundation.

Conclusion

As Anaheim Bio embarks on this transformative journey, the biotechnology landscape anticipates significant advancements in the treatment of CPPD. With promising financial support and a focused vision, the company positions itself to make a substantial impact in the field of rheumatology, potentially changing the lives of millions of affected individuals. For more information about Anaheim Bio and its innovative research, you can visit their official website at anaheimbio.com.